INMB Earnings Inmune Bio, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–20 of 20
| Q2 2026 | 2026-06-30 | -0.25 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.20 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -1.86 | 2026-03-30 | 10-K |
| Q3 2025 | 2025-09-30 | -1.68 | 2025-10-30 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.49 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.43 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -2.11 | 2026-03-30 | 10-K |
| Q3 2025 | 2024-09-30 | -1.71 | 2025-10-30 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.11 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.61 | 2025-05-08 | 10-Q |
| FY 2024 | 2023-12-31 | -1.67 | 2025-03-27 | 10-K |
| Q3 2024 | 2023-09-30 | -1.20 | 2024-10-31 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.73 | 2024-08-01 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.36 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -1.52 | 2024-03-28 | 10-K |
| Q3 2023 | 2022-09-30 | -1.20 | 2023-11-01 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.77 | 2023-08-07 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.39 | 2023-05-03 | 10-Q |
| FY 2022 | 2021-12-31 | -1.88 | 2023-03-02 | 10-K |
| Q3 2022 | 2021-09-30 | -1.33 | 2022-11-02 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.